Zota Health Care LImited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
ZOTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zota Health Care has filed a quarterly compliance report confirming that proceeds from three separate preferential issues have been used in line with the originally stated objects, with no deviation or variation. The first issue (Rs 17,907.28 lakhs total) has seen Rs 10,908.37 lakhs received so far, of which about Rs 10,498 lakhs has been deployed — largely into expanding the DAVAINDIA project (Rs 8,230 lakhs) and working capital (Rs 1,919 lakhs). The second issue (Rs 12,341 lakhs total) has received Rs 7,713 lakhs, with Rs 6,378 lakhs already spent mainly on DAVAINDIA COCO expansion (Rs 2,894 lakhs) and general corporate purposes (Rs 1,694 lakhs). A third, more recent issue of Rs 7,155 lakhs raised on April 17, 2025 has not yet seen any deployment during the quarter. CRISIL Ratings is monitoring the first two issues, and the Audit Committee has confirmed no deviations.
This is a routine regulatory filing indicating disciplined use of raised capital toward stated growth plans (DAVAINDIA retail pharmacy expansion), which is mildly positive for shareholder confidence. However, the April 2025 funds are still untouched, and over Rs 11,600 lakhs across issues is still pending receipt from warrant conversions, so investors should track deployment timelines.